Jenny Erazo, LCSW in Logan, UT - Counselor

Jenny Erazo, LCSW is a Counselor - Mental Health based in Logan, Utah. Jenny Erazo is licensed to practice in * (Not Available) (license number ) and her current practice location is 195 E 700 N, Logan, Utah. She can be reached at her office (for appointments etc.) via phone at (435) 213-6696.

NPI number for Jenny Erazo is 1770873184 and her current mailing address is 1140 36th St Ste 270, Ogden, Utah. She does not participate in medicare program and thus does not accept medicare assignments. Her NPI Number is 1770873184.

Contact Information

	Jenny Erazo, LCSW
	195 E 700 N, Logan, UT 84321-3323
	(435) 213-6696
	Not Available

Healthcare Provider's Profile

Full Name	Jenny Erazo
Gender	Female
Speciality	Counselor - Mental Health
Location	195 E 700 N, Logan, Utah
Accepts Medicare Assignments	Does not participate in Medicare Program. She may not accept medicare assignment.

NPI Data:

NPI Number: 1770873184
Provider Enumeration Date: 04/19/2011
Last Update Date: 01/13/2023

Medical Identifiers

Medical identifiers for Jenny Erazo such as npi, medicare ID, medicare PIN, medicaid, etc.

Identifier	Type	State	Issuer
1770873184	NPI	-	NPPES

Medical Taxonomies and Licenses

Taxonomy	Type	License (State)	Status
1041C0700X	Social Worker - Clinical	(* (Not Available))	Secondary
101YM0800X	Counselor - Mental Health	(* (Not Available))	Primary

Medicare Part D Prescriber Enrollment

Any physician or other eligible professional who prescribes Part D drugs must either enroll in the Medicare program or opt out in order to prescribe drugs to their patients with Part D prescription drug benefit plans. Jenny Erazo is NOT enrolled with medicare and thus cannot prescribe medicare part D drugs to patients with medicare part D benefits.

Mailing Address and Practice Location

Mailing Address	Practice Location Address
Jenny Erazo, LCSW 1140 36th St Ste 270, Ogden, UT 84403-2064 Ph: () -	Jenny Erazo, LCSW 195 E 700 N, Logan, UT 84321-3323 Ph: (435) 213-6696

News Archive

Amgen presents data from several romosozumab and Prolia at ASBMR 2013 Annual Meeting

Amgen today announced that it will present data from several romosozumab and Prolia® (denosumab) studies at the American Society for Bone and Mineral Research (ASBMR) 2013 Annual Meeting in Baltimore from Oct. 4-7, 2013.

Scientist develops new method for identifying proteins to build new biologics

A University of Toronto scientist has developed a new method for identifying the raw ingredients necessary to build 'biologics', a powerful class of medications that has revolutionized treatment of diseases like rheumatoid arthritis and some cancers.

Redefinition of cardiac hypertrophy term needed

The European Society of Cardiology (ESC) Working Group on Myocardial Function is calling for a redefinition of the term cardiac hypertrophy which is currently used to describe changes to the morphology (structure) of the heart. Instead the position paper, published online today in the European Journal of Heart Failure, suggests that use of the general term myocardial remodelling should be preferred.

Researcher explores biological processes that cause fertility problems in humans

With significant funding from the National Institutes of Health (NIH), a researcher at The University of Texas at Arlington is investigating fundamental biological processes that lead to fertility problems in humans.

Decrease in physician reimbursement leads to decline in AST usage for prostate cancer

The use of androgen suppression therapy (AST) in prostate cancer for low-risk cases declined following a decrease in physician reimbursement, according to a study published online TK in The Journal of the National Cancer Institute. However, the indicated use of AST for metastatic disease in the palliative setting did not decline in the same period.

Jenny Erazo, LCSW - in Logan, UT